The GNPDA2 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the GNPDA2 gene has been disrupted to create a loss-of-function model for hexosamine pathway studies. This polyclonal pool contains a heterogeneous mix of edited alleles, enabling functional screening and metabolic analysis without clonal selection.
The HAP1 cell line is a near-haploid, fibroblast-like line derived from the KBM-7 cell line of a male patient with chronic myeloid leukemia in blast crisis. These cells exhibit hemopoietic origin and are deficient in p53, providing a robust genetic background for studying gene function in a leukemia-relevant context. Their near-haploidy facilitates knockout generation and functional interrogation of genes involved in metabolism and signaling.
GNPDA2 encodes glucosamine-6-phosphate deaminase 2, catalyzing deamination of glucosamine-6-phosphate to fructose-6-phosphate, a critical step linking hexosamine metabolism to glycolysis and N-glycan biosynthesis. Its activity is modulated by upstream regulators such as insulin signaling, glucose availability, and glutamine-derived hexosamine flux. Downstream, GNPDA2 influences glycolytic intermediates, UDP-GlcNAc levels, and subsequent protein O-GlcNAcylation and N-glycosylation. It interacts with hexosamine pathway components GFPT1, GNPNAT1, PGM3, and UAP1; its knockout disrupts hexosamine flux, altering OGT and MGEA5-mediated O-GlcNAc cycling and potentially impairing nutrient-responsive signaling.
In the HAP1 background, GNPDA2 loss-of-function provides a relevant model to study hexosamine-dependent glycosylation and nutrient sensing in a hemopoietic cell type with deficient p53. The interplay between hexosamine flux and p53-mediated stress responses may influence cellular metabolism and survival decisions in leukemic cells. This system enables dissection of how hexosamine pathway intermediates contribute to N-glycosylation and O-GlcNAcylation in a cancer-relevant model, with implications for understanding metabolic reprogramming in leukemia and other hematological malignancies.
Researchers can employ this knockout model to study hexosamine pathway regulation, N-glycosylation defects, obesity and diabetes mechanisms, metabolic flux, and drug target validation for metabolic diseases. Recommended assays include western blotting for O-GlcNAc and glycosylated proteins, RT-qPCR for glycosylation genes, labeled glucose flux analysis, enzyme activity assays, lectin-based flow cytometry, insulin sensitivity tests, and cellular ATP/NAD+ measurements. For further details, please contact Ascent Research.
